News Sentiment

MNPR sentiment intelligence

Monopar Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 106.60 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

85/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+9.0% over one week, +78.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Monopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy)

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 85/100 classification
One-week reaction 9.0% Price confirming higher
Trend fit Trend active 78.4% over four weeks
Fair value 247.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 41
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
TradingView 9
Market source 8
GlobeNewswire 5
simplywall.st 3
Seeking Alpha 2
Stock Traders Daily 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 13
Balance sheet 2
Regulatory and legal 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Investing.com South Africa Direct company coverage

Cantor Fitzgerald reiterates Monopar stock Overweight rating at $109 By Investing.com

Cantor Fitzgerald has reiterated an Overweight rating and a $109 price target for Monopar Therapeutics (NASDAQ:MNPR), ahead of an expected New Drug Application submission for ALXN1840 for Wilson disease. The firm highlighted Monopar's significant stock return and upward earnings

Tone
Positive 74/100
Event
Analyst action
Published
15 Jul 2026 22:11
Source
Investing.com South Africa
TradingView Direct company coverage

Price to sales forward of Monopar Therapeutics Inc – DUS:1IY0

This article displays the "Price to sales forward" financial metric for Monopar Therapeutics Inc (DUS:1IY0) on the TradingView platform. It shows that there are no recorded trades for the period and highlights data sources like ICE Data Services and FactSet. The content primarily

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 03:42
Source
TradingView
Stock Traders Daily Direct company coverage

(MNPR) Movement as an Input in Quant Signal Sets

This article analyzes Monopar Therapeutics Inc. (NASDAQ: MNPR) using AI-driven quantitative signals. It highlights strong sentiment across all horizons supporting an overweight bias and details three institutional trading strategies: Position Trading, Momentum Breakout, and Risk

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 08:50
Source
Stock Traders Daily
RTTNews Direct company coverage

Biotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT

Several biotech companies, including First Tracks Biotherapeutics (TRAX), BridgeBio Pharma (BBIO), Monopar Therapeutics (MNPR), 10x Genomics (TXG), and MapLight Therapeutics (MPLT), reached 52-week highs on July 9, 2026. These gains were propelled by positive developments such as

Tone
Positive 72/100
Event
Market update
Published
11 Jul 2026 07:39
Source
RTTNews
Stock Titan Direct company coverage

MNPR (MNPR): Arthur Klausner files Form 144/A to sell 5,000 shares

Arthur Klausner has filed a Form 144/A indicating his intent to sell up to 5,000 common shares of Monopar Therapeutics (MNPR) through MLPFS on NASDAQ, effective on or after July 8, 2026. These shares originated from restricted stock unit vestings between 2020 and 2023 as part of

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 21:39
Source
Stock Titan
AD HOC NEWS Direct company coverage

MNPR stock. Monopar Therapeutics stays tied to its clinical pipeline.

Monopar Therapeutics Inc. (MNPR) is a small-cap clinical-stage biotechnology company listed on Nasdaq, with its valuation closely linked to its development-stage pipeline. The company focuses on developing therapies for oncology and rare diseases, with its lead program, ALXN1840,

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 17:01
Source
AD HOC NEWS
Stock Titan Direct company coverage

Monopar Therapeutics SEC Filing

This article reports on Monopar Therapeutics' SEC Form 144 filing, which details a proposed sale of 5,000 shares of Class A securities by Arthur Klausner on July 7, 2026, with an aggregate market value of $485,250. The filing indicates the securities were acquired on August 13, 2

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 02:28
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBIT forward of Monopar Therapeutics Inc. – NASDAQ:MNPR

The article focuses on the enterprise value to EBIT forward ratio for Monopar Therapeutics Inc. (NASDAQ: MNPR), presenting financial data for the company. It appears to be a financial data point or metric displayed within the TradingView platform, without additional commentary or

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 17:09
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 4 Monopar Therapeutics Inc For: 2 July By Investing.com

This article from Investing.com announces the filing of Form 4 for Monopar Therapeutics Inc., dated July 2nd. It briefly mentions the company's stock symbol MNPR and its share price performance on that day. The article is primarily a placeholder for the SEC filing announcement.

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 17:09
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Monopar Therapeutics (MNPR) CFO nets shares from RSU vesting and tax withholding

Monopar Therapeutics' CFO, Vu Quan Anh, reported routine equity compensation activity involving restricted stock units (RSUs). On June 30, 2026, 1,228 RSUs vested, converting to common shares, with 507 shares withheld by the company for tax obligations. Following these transactio

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 23:09
Source
Stock Titan
Stock Titan Direct company coverage

Monopar Therapeutics (MNPR) CEO nets shares after RSU vesting and tax withholding

Monopar Therapeutics CEO Chandler Robinson had 12,873 restricted stock units vest into common shares on June 30, 2026. To cover tax obligations, 4,084 shares were withheld by the issuer at $92.59 per share. Following these transactions, Robinson directly holds 99,267 shares and i

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 23:09
Source
Stock Titan
Stock Titan Direct company coverage

Monopar Therapeutics (MNPR) COO gains stock via RSU vesting and tax withholding

Monopar Therapeutics COO Andrew Cittadine converted 5,254 restricted stock units (RSUs) into common stock on June 30, 2026, with 2,309 shares withheld by the company for tax purposes. Following these routine transactions, Cittadine directly holds 57,923 shares of Monopar common s

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 23:09
Source
Stock Titan
Stock Traders Daily Direct company coverage

Liquidity Mapping Around (MNPR) Price Events

This article provides a liquidity mapping analysis for Monopar Therapeutics Inc. (NASDAQ: MNPR), highlighting strong sentiment across all time horizons. It details several AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-ti

Tone
Positive 71/100
Event
Balance sheet
Published
02 Jul 2026 07:41
Source
Stock Traders Daily
Stock Titan Direct company coverage

Monopar Therapeutics (MNPR) director Nicole Sweeny files initial Form 3

Monopar Therapeutics director Nicole Sweeny has filed an initial Statement of Beneficial Ownership on Form 3, establishing her as an insider of the company. This filing, accepted by the SEC on June 30, 2026, indicates her role as a director but does not report any stock transacti

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 03:10
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Monopar Therapeutics Inc For: 30 June By Investing.com

This article announces the filing of Form 4 for Monopar Therapeutics Inc. for the period ending June 30th. It is a brief news item from Investing.com, accompanied by current market data for various indices, commodities, and stocks. The company's stock symbol MNPR is noted with a

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 03:04
Source
Investing.com Canada
The Manila Times Direct company coverage

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

Monopar Therapeutics announced that the FDA granted Rare Pediatric Disease (RPD) designation to ALXN1840 for Wilson disease. This designation could lead to a pediatric Priority Review Voucher upon NDA approval, expediting the review process for future marketing applications. ALXN

Tone
Positive 76/100
Event
Regulatory and legal
Published
30 Jun 2026 12:10
Source
The Manila Times
Stock Titan Direct company coverage

FDA grants Rare Pediatric Disease designation to Monopar (MNPR) Wilson disease drug ALXN1840

Monopar Therapeutics (MNPR) announced that the FDA has granted Rare Pediatric Disease (RPD) designation to its late-stage drug candidate, ALXN1840, for the treatment of Wilson disease. This designation could provide Monopar with a pediatric Priority Review Voucher upon ALXN1840's

Tone
Positive 71/100
Event
Market update
Published
30 Jun 2026 12:09
Source
Stock Titan
Stock Titan Direct company coverage

FDA rare pediatric disease tag could speed ALXN1840’s path for Wilson disease

Monopar Therapeutics announced that its late-stage candidate ALXN1840 for Wilson disease has received Rare Pediatric Disease (RPD) designation from the FDA. This designation makes Monopar eligible for a potential pediatric Priority Review Voucher upon NDA approval, which could ex

Tone
Positive 71/100
Event
Regulatory and legal
Published
30 Jun 2026 12:09
Source
Stock Titan
TradingView Direct company coverage

Price to book forward of Monopar Therapeutics Inc. – NASDAQ:MNPR

This article provides the "Price to book forward" metric for Monopar Therapeutics Inc. (NASDAQ: MNPR). It is a finance-related page from TradingView, focusing on the company's financial data.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 15:41
Source
TradingView
www.marketscreener.com Direct company coverage

Monopar Therapeutics Inc.(NasdaqCM: MNPR) added to Russell 2000 Value Benchmark

Monopar Therapeutics Inc. (NasdaqCM:MNPR), a clinical-stage biopharmaceutical company focused on treatments for Wilson disease and radiopharmaceuticals for oncology, has been added to the Russell 2000 Value Benchmark. The company's stock experienced a significant 7.85% increase,

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 15:40
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to Russell Microcap Value Benchmark Index

Monopar Therapeutics Inc. (NasdaqCM:MNPR) has been added to the Russell Microcap Value Benchmark Index. The clinical-stage biopharmaceutical company focuses on treatments for Wilson disease and developing novel radiopharmaceuticals for oncology. This inclusion in the Russell

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 13:40
Source
www.marketscreener.com
Simply Wall Street Direct company coverage

Monopar Therapeutics Insiders Make Handsome Sum Selling Stock At US$67.15 Per Share

Monopar Therapeutics' stock recently rose 28%, but insiders who sold shares in the last year missed out on higher valuations. While the biggest insider sale by Arthur Klausner was for US$344k at US$68.09 per share, below the current price of US$87.68, insiders still own 7.0% of t

Tone
Negative 36/100
Event
Market update
Published
29 Jun 2026 10:40
Source
Simply Wall Street
TradingView Direct company coverage

Price to earnings forward of Monopar Therapeutics Inc. – NASDAQ:MNPR

This page from TradingView provides a financial overview of Monopar Therapeutics Inc. (NASDAQ: MNPR), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of viewing, with no trades occurring. The content is primarily a

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 05:40
Source
TradingView